From Sarah at Retrotope regarding RT001 Clinical Trials for PSP!
Do not lose hope. Retrotope is in the process of developing drugs to treat a variety of neurological diseases, and PSP is a disease that we intend to target. We have treated a few patients in the US with our investigational drug candidate RT001 in a small Expanded Access cohort, and we have seen encouraging results. These results have prompted us to plan a formal clinical trial for PSP and this is likely to begin sometime in summer 2020.
The trial will take place at several centers within the United States. If a patient with PSP meets all trial criteria and is willing and able to travel every few months to a U.S. medical center that is participating in the trial, she or he may be able to enroll in our study.
As the trial start nears, a formal listing regarding the trial and participating clinical trial sites will be posted on https://clinicaltrials.gov/. With your permission, I can additionally add you to my list of patients/families to notify at the appropriate time. Please let me know.
Kind regards,
Sarah
Sarah Endemann, MSc, CCRC
Clinical Coordinator
Retrotope, Inc.
4300 El Camino Real, Ste. 201
Los Altos, CA 94022
Tel: 619.206.5944
Fax: 650.209.5007
sarah@retrotope.com
www.retrotope.com
